Healthcare provider profile · identity verified

Austin Saavedra, MD

Family Practice · FOLSOM, CA · NPI 1265884191

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	431	131
Levothyroxine Sodium	Levothyroxine Sodium	380	103
Amlodipine Besylate	Amlodipine Besylate	315	93
Lisinopril	Lisinopril	228	71
Losartan Potassium	Losartan Potassium	225	73
Omeprazole	Omeprazole	184	52
Gabapentin	Gabapentin	180	52
Metformin Hcl	Metformin Hcl	176	53
Tamsulosin Hcl	Tamsulosin Hcl	164	49
Metoprolol Succinate	Metoprolol Succinate	137	39
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	120	29
Hydrochlorothiazide	Hydrochlorothiazide	110	29
Pantoprazole Sodium	Pantoprazole Sodium	102	33
Albuterol Sulfate Hfa	Albuterol Sulfate	101	49
Simvastatin	Simvastatin	93	27
Rosuvastatin Calcium	Rosuvastatin Calcium	90	29
Carvedilol	Carvedilol	88	24
Furosemide	Furosemide	88	31
Meloxicam	Meloxicam	81	36
Eliquis	Apixaban	78	19
Ozempic	Semaglutide	76	13
Zolpidem Tartrate	Zolpidem Tartrate	75	11
Fluticasone Propionate	Fluticasone Propionate	70	30
Hydroxyzine Hcl	Hydroxyzine Hcl	70	20
Allopurinol	Allopurinol	64	21
Montelukast Sodium	Montelukast Sodium	64	20
Metoprolol Tartrate	Metoprolol Tartrate	61	23
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	60	16
Sertraline Hcl	Sertraline Hcl	58	19
Alprazolam	Alprazolam	57	14
Famotidine	Famotidine	53	16
Valsartan	Valsartan	53	18
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	52	25
Potassium Chloride	Potassium Chloride	50	18
Oxybutynin Chloride	Oxybutynin Chloride	47	suppressed
Januvia	Sitagliptin Phosphate	43	11
Trazodone Hcl	Trazodone Hcl	41	12
Azithromycin	Azithromycin	39	29
Finasteride	Finasteride	39	14
Lorazepam	Lorazepam	38	11
Mirtazapine	Mirtazapine	38	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	37	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	37	suppressed
Duloxetine Hcl	Duloxetine Hcl	35	12
Tramadol Hcl	Tramadol Hcl	34	14
Celecoxib	Celecoxib	33	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	33	suppressed
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Xarelto	Rivaroxaban	30	suppressed
Atenolol	Atenolol	29	suppressed
Clonazepam	Clonazepam	29	suppressed
Spironolactone	Spironolactone	29	suppressed
Alendronate Sodium	Alendronate Sodium	27	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	27	23
Ibuprofen	Ibuprofen	26	12
Liothyronine Sodium	Liothyronine Sodium	26	suppressed
Metformin Hcl Er	Metformin Hcl	26	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	25	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Ondansetron Hcl	Ondansetron Hcl	25	13
Tizanidine Hcl	Tizanidine Hcl	24	11
Baclofen	Baclofen	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Prednisone	Prednisone	22	16
Azelastine Hcl	Azelastine Hcl	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Glipizide	Glipizide	20	suppressed
Glipizide Er	Glipizide	20	suppressed
Lansoprazole	Lansoprazole	20	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	17
Glimepiride	Glimepiride	19	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	19	19
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Tradjenta	Linagliptin	18	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	18	suppressed
Bupropion Xl	Bupropion Hcl	17	suppressed
Creon	Lipase/Protease/Amylase	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Fenofibrate	Fenofibrate,micronized	16	suppressed
Methocarbamol	Methocarbamol	16	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Jardiance	Empagliflozin	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Mupirocin	Mupirocin	14	14
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	11
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Estradiol	Estradiol	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Xifaxan	Rifaximin	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Constulose	Lactulose	11	suppressed
Naproxen	Naproxen	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error